Peptic ulcer disease (PUD) remains a prevalent condition worldwide, necessitating an updated understanding of its pathophysiology, diagnosis, and treatment. This article presents a comprehensive approach to PUD, highlighting recent advancements in management and treatment strategies.
While Helicobacter pylori and nonsteroidal anti-inflammatory drugs (NSAIDs) remain the primary etiological agents, recent studies underscore the role of genetic predisposition, stress, and other lifestyle factors. An individualized approach to PUD, considering these multifactorial causes, optimizes patient outcomes.
Endoscopy continues to be the gold standard for PUD diagnosis. However, non-invasive tests like urea breath tests, stool antigen tests, and serologic tests for H. pylori have gained prominence due to their convenience and accuracy.
First-line treatment for PUD involves eradicating H. pylori with triple or quadruple therapy, alongside proton pump inhibitors (PPIs). For NSAID-induced ulcers, discontinuation of NSAIDs and PPI therapy are recommended. Recent advancements include the use of vonoprazan, a potassium-competitive acid blocker, showing superior efficacy to PPIs in certain populations. Moreover, the role of probiotics in enhancing H. pylori eradication and reducing side effects of antibiotics is gaining recognition.
Healthcare professionals must educate patients about lifestyle modifications, such as avoiding NSAIDs, limiting alcohol, and cessation of smoking. Emphasizing the importance of adherence to medication regimens is crucial to prevent recurrence.
Managing PUD effectively requires an updated, comprehensive approach considering the latest advancements in pathophysiology, diagnosis, and treatment. An individualized treatment plan, coupled with patient education, can significantly improve patient outcomes and prevent recurrence. As healthcare professionals, our role in staying abreast with these updates and implementing them in practice is vital.
1.
Chemotherapy Boosts Survival for Older Patients With TNBC
2.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
3.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
4.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
5.
Biden's Bedtime Cancer Symptom; Top Cancer Hospitals; FDA Panel to Review MCED Test
1.
Consensus Recommendations for Healthy Hematologic Aging
2.
Exploring the Role of Fecal Leukocytes in Intestinal Health
3.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
4.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
5.
Clinical Pharmacology of Ferroptosis-Modulating Anticancer Pharmacotherapy
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Chemotherapy: What to Expect
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation